Name: UMIN ID:
Unique ID issued by UMIN | UMIN000010638 |
---|---|
Receipt number | R000012439 |
Scientific Title | Phase II study of cetuximab rechallenge in the third-line therapy in patients with KRAS wild-type metastatic colorectal cancer |
Date of disclosure of the study information | 2013/05/07 |
Last modified on | 2019/03/08 09:56:15 |
No. | Disposal | Last modified on | Item of update | |
---|---|---|---|---|
1 | Insert | 2013/05/02 18:28:18 | ||
2 | Update | 2013/05/03 08:29:07 | Email |
|
3 | Update | 2013/11/02 09:12:23 | TEL |
|
4 | Update | 2013/11/20 11:44:21 | TEL Last name of contact person Last name of contact person Organization Institutions |
|
5 | Update | 2013/11/20 12:58:29 | Last name of contact person Last name of contact person |
|
6 | Update | 2016/05/02 09:20:33 | Name of primary person or sponsor Organization |
|
7 | Update | 2016/11/15 13:23:27 | Key inclusion criteria |
|
8 | Update | 2016/11/15 13:25:27 | Recruitment status Last follow-up date Date of closure to data entry Date trial data considered complete Date analysis concluded Publication of results |
|
9 | Update | 2019/03/08 09:56:15 | Recruitment status Date trial data considered complete Date analysis concluded |